We serve Chemical Name:Pyrazine-2,5-dicarboxylic acid CAS:122-05-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Pyrazine-2,5-dicarboxylic acid
CAS.NO:122-05-4
Synonyms:MFCD01630902;PYRAZINE-2,5-DICARBOXYLIC ACID;2,5-Pyrazinedicarboxylic acid
Molecular Formula:C6H4N2O4
Molecular Weight:168.107
HS Code:2933990090
Physical and Chemical Properties:
Melting point:220-230°C
Boiling point:466.5±45.0 °C at 760 mmHg
Density:1.7±0.1 g/cm3
Index of Refraction:1.638
PSA:100.38000
Exact Mass:168.017105
LogP:-2.01
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD01630902 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,5-Pyrazinedicarboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,5-Pyrazinedicarboxylic acid Use and application,MFCD01630902 technical grade,usp/ep/jp grade.
Related News: Zynteglo was granted conditional marketing authorisation in May 2019. The conditional authorisation means that there is more evidence to come about the medicine, which the company will provide. EMA regularly reviews new information that becomes available. Bromo-(2,4-dichloro-phenoxy)-acetic acid cyclohexyl ester manufacturers Joan Merrill, Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Research Program, US, said: “Arthritis and rash are the most common and persistent problems in lupus and often have a significant impact on a person’s life. The strength of the data from this analysis is that anifrolumab was found to be consistently effective using three different ways of looking at rash and three different approaches to arthritis. (2R,3S,4R)-4-Benzyloxy-2-(tert-butyl-diphenyl-silanyloxymethyl)-3,4-dihydro-2H-pyran-3-ol suppliers For skin rash, the difference in response rates for anifrolumab versus placebo at week 52 were 13.5% SLE Disease Activity Index (SLEDAI), 15.5% British Isles Lupus Assessment Group index (BILAG) and 15.6% modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI). For arthritis, differences in response rates were 8.2% SLEDAI, 11.8% BILAG and 12.6% joint response. ethyl 2-isopropyl-5-methylcyclohexylidenecyanoacetate vendor & factory.
